Advertisement

Psychopharmacology

, Volume 231, Issue 7, pp 1389–1395 | Cite as

Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine

  • Josep Antoni Ramos-Quiroga
  • Margarida Corominas-RosoEmail author
  • Gloria Palomar
  • Nuria Gomez-Barros
  • Marta Ribases
  • Cristina Sanchez-Mora
  • Rosa Bosch
  • Mariana Nogueira
  • Montserrat Corrales
  • Sergi Valero
  • Miguel Casas
Original Investigation

Abstract

Rationale

Atomoxetine (ATX) is a non-stimulant drug approved for the treatment of attention deficit hyperactivity disorder (ADHD). Although animal models have provided evidence that brain-derived neurotrophic factor (BDNF) is involved in the effects of ATX in the brain, there are no studies of BDNF in ADHD patients undergoing treatment with ATX.

Objectives

The aim of this study was to evaluate the possible changes in serum levels of BDNF in adults treated with ATX and its relationship with clinical improvement.

Methods

A total of 54 adults with ADHD (age 33.43 ± 8.99 years) without any medical or psychiatric comorbidities were treated with ATX for 3 months; 35 of them completed the protocol. The clinical data for ADHD diagnosis, including Conners’ ADHD Rating Scale and blood samples, were collected at baseline (V1) and at the end of the treatment (V2).

Results

Adults with ADHD who completed ATX treatment for 3 months showed a significant improvement in their clinical symptoms. No significant differences were found in BDNF levels before and after treatment with ATX in the whole group of patients (p = 0.15). The inattentive subgroup of ATX responders showed a decrease of serum BDNF after 3 months of ATX treatment (p = 0.05) not present in the combined subtype (p = 0.82).

Conclusions

These results suggest that BDNF is not directly involved in the neurobiological mechanisms of ATX-induced improvement of clinical symptoms of ADHD. The differences between the combined and inattentive subtypes in serum BDNF changes suggest selective ATX-induced effects in the function of brain circuitry.

Keywords

Brain-derived neurotrophic factor BDNF ADHD Atomoxetine Neuroplasticity 

Notes

Acknowledgments

We would like to thank the Neurovascular Research Laboratory of Vall d’Hebron University Hospital and particularly Ms. Anna Penalba for her assistance with the biochemical analyses. Dr. Marta Ribases is a recipient of a Miguel Servet contract from the “Instituto de Salud Carlos III,” Spain. We also thank the collaboration of Alonso Montoya for the suggestions.

Conflict of interest

Josep Antoni Ramos-Quiroga was on the speakers bureau and/or acted as consultant for Almirall, Eli-Lilly, Janssen-Cilag, Novartis, Shire, and Rubió within the last 3 years. He also received travel awards (airfare + hotel) from Janssen-Cilag, Shire, Rubió, and Eli-Lilly to take part in psychiatric meetings. The ADHD Program that he chaired received unrestricted educational and research support from the following pharmaceutical companies in the last 3 years: Eli-Lilly, Janssen-Cilag, Shire, and Rubió.

The other authors report no biomedical financial interests or potential conflicts of interest.

References

  1. Adriani W, Leo D, Greco D, Rea M, di Porzio U, Laviola G, Perrone-Capano C (2006) Methylphenidate administration to adolescent rats determines plastic changes on reward-related behavior and striatal gene expression. Neuropsychopharmacology 31:1946–1956PubMedCrossRefGoogle Scholar
  2. Aicardi G, Argilli E, Cappello S, Santi S, Riccio M, Thoenen H, Canossa M (2004) Induction of long-term potentiation and depression is reflected by corresponding changes in secretion of endogenous brain-derived neurotrophic factor. Proc Natl Acad Sci U S A 101:15788–15792PubMedCentralPubMedCrossRefGoogle Scholar
  3. Bekinschtein P, Cammarota M, Medina JH (2013) BDNF and memory processing. Neuropharmacology. doi: 10.1016/j.neuropharm.2013.04.024 PubMedGoogle Scholar
  4. Bergman O, Westberg L, Lichtenstein P, Eriksson E, Larsson H (2011) Study on the possible association of brain-derived neurotrophic factor polymorphism with the developmental course of symptoms of attention deficit and hyperactivity. Int J Neuropsychopharmacol 14:1367–1376PubMedCrossRefGoogle Scholar
  5. Britton GB (2011) Cognitive and emotional behavioural changes associated with methylphenidate treatment: a review of preclinical studies. Int J Neuropsychopharmacol. doi: 10.1017/S1461145711000472 PubMedGoogle Scholar
  6. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711PubMedCrossRefGoogle Scholar
  7. Chamberlain SR, Hampshire A, Müller U et al (2009) Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry 65:550–555PubMedCrossRefGoogle Scholar
  8. Chapleau CA, Larimore JL, Theibert A, Pozzo-Miller L (2009) Modulation of dendritic spine development and plasticity by BDNF and vesicular trafficking: fundamental roles in neurodevelopmental disorders associated with mental retardation and autism. J Neurodev Disord 1:185–196PubMedCentralPubMedCrossRefGoogle Scholar
  9. Conners J, Erhardt D, Sparrow E (1999) Conners’ Adult ADHD Diagnostic Interview for DSM-IV. Multi-Health Systems, Nord Tonawanda, NYGoogle Scholar
  10. Contini V, Rovaris DL, Victor MM, Grevet EH, Rohde LA, Bau CH (2012) Pharmacogenetics of response to methylphenidate in adult patients with attention-deficit/hyperactivity disorder (ADHD): a systematic review. Eur Neuropsychopharmacol 23:555–560PubMedCrossRefGoogle Scholar
  11. Corominas M, Roncero C, Ribases M, Castells X, Casas M (2007) Brain-derived neurotrophic factor and its intracellular signaling pathways in cocaine addiction. Neuropsychobiology 55:2–13PubMedCrossRefGoogle Scholar
  12. Corominas-Roso M, Ramos-Quiroga JA, Ribases M et al (2013) Decreased serum levels of brain-derived neurotrophic factor in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. doi: 10.1017/S1461145712001629 PubMedGoogle Scholar
  13. Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP, Castellanos FX (2012) Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies. Am J Psychiatry 169:1038–1055PubMedCrossRefGoogle Scholar
  14. Del’guidice T, Lemasson M, Etiévant A, Manta S, Magno LA, Escoffier G, Roman FS, Beaulieu JM (2013) Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice. Psychopharmacology (Berl). doi: 10.1007/s00213-013-3212-8 Google Scholar
  15. Dillo W, Göke A, Prox-Vagedes V, Szycik GR, Roy M, Donnerstag F, Emrich HM, Ohlmeier MD (2010) Neuronal correlates of ADHD in adults with evidence for compensation strategies—a functional MRI study with a Go/No-Go paradigm. Ger Med Sci. doi: 10.3205/000098 PubMedCentralPubMedGoogle Scholar
  16. Dincheva I, Glatt CE, Lee FS (2012) Impact of the BDNF Val66Met polymorphism on cognition: implications for behavioral genetics. Neuroscientist 18:439–451PubMedCentralPubMedCrossRefGoogle Scholar
  17. Fumagalli F, Racagni G, Colombo E, Riva MA (2003) BDNF gene expression is reduced in the frontal cortex of dopamine transporter knockout mice. Mol Psychiatry 8:898–899PubMedCrossRefGoogle Scholar
  18. Fumagalli F, Cattaneo A, Caffino L, Ibba M, Racagni G, Carboni E, Gennarelli M, Riva MA (2010) Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate. Pharmacol Res 62:523–529PubMedCrossRefGoogle Scholar
  19. Grimm JW, Lu L, Hayashi T, Hope BT, Su TP, Shaham Y (2003) Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci 23:742–747PubMedGoogle Scholar
  20. Karege F, Schwald M, Cisse M (2002) Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328:261–264PubMedCrossRefGoogle Scholar
  21. Kent L, Green E, Hawi Z et al (2005) Association of the paternally transmitted copy of common Valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene with susceptibility to ADHD. Mol Psychiatry 10:939–943PubMedCrossRefGoogle Scholar
  22. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, Knudsen GM, Aznar S (2011) Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 14:347–353PubMedCrossRefGoogle Scholar
  23. Koneski JAS, Casella EB, Agertt F, Ferreira MG (2011) Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: a Brazilian sample study and literature review. Epilepsy Behav 21:228–232PubMedCrossRefGoogle Scholar
  24. Kuntsi J, Klein C (2012) Intraindividual variability in ADHD and its implications for research of causal links. Curr Top Behav Neurosci 9:67–91PubMedCrossRefGoogle Scholar
  25. Lang UE, Hellweg R, Sander T, Gallinat J (2009) The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry 14:120–122PubMedCrossRefGoogle Scholar
  26. Lanktree M, Squassina A, Krinsky M, Strauss J, Jain U, Macciardi F, Kennedy JL, Muglia P (2008) Association study of brain-derived neurotrophic factor (BDNF) and LIN-7 homolog (LIN-7) genes with adult attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 147B:945–951PubMedCrossRefGoogle Scholar
  27. Lee TH, Lee CH, Kim IH, Yan BC, Park JH, Kwon SH, Park OK, Ahn JH, Cho JH, Won MH, Kim SK (2012) Effects of ADHD therapeutic agents, methylphenidate and atomoxetine, on hippocampal neurogenesis in the adolescent mouse dentate gyrus. Neurosci Lett 524:84–88PubMedCrossRefGoogle Scholar
  28. Lüscher C, Malenka RC (2011) Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 69:650–663PubMedCrossRefGoogle Scholar
  29. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose–response study. Pediatrics 108:E83PubMedCrossRefGoogle Scholar
  30. Molendijk ML, Haffmans JPM, Bus BA, Spinhoven P, Penninx BW, Prickaerts J, Oude Voshaar RC, Elzinga BM (2012) Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight. PLoS ONE 7:e48046PubMedCentralPubMedCrossRefGoogle Scholar
  31. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ (1998) Transport of brain-derived neurotrophic factor across the blood–brain barrier. Neuropharmacology 37:1553–1561PubMedCrossRefGoogle Scholar
  32. Ramos-Quiroga JA, Bosch R, Richarte V et al (2012) Criterion and concurrent validity of Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) Spanish version. Rev Psiquiatr Salud Ment 5:229–235PubMedCrossRefGoogle Scholar
  33. Sánchez-Mora C, Ribasés M, Ramos-Quiroga JA et al (2010) Meta-analysis of brain-derived neurotrophic factor p.Val66Met in adult ADHD in four European populations. Am J Med Genet B Neuropsychiatr Genet 153B:512–523PubMedGoogle Scholar
  34. Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, Danker-Hopfe H, Gass P (2009) Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 42:270–276PubMedCrossRefGoogle Scholar
  35. Schulz KP, Fan J, Bédard A-CV, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH (2012) Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 69:952–961PubMedCrossRefGoogle Scholar
  36. Shim S-H, Hwangbo Y, Kwon Y-J, Jeong HY, Lee BH, Lee HJ, Kim YK (2008) Increased levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention deficit-hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry 32:1824–1828PubMedCrossRefGoogle Scholar
  37. Sonuga-Barke EJS, Castellanos FX (2007) Spontaneous attentional fluctuations in impaired states and pathological conditions: a neurobiological hypothesis. Neurosci Biobehav Rev 31:977–986PubMedCrossRefGoogle Scholar
  38. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693–695PubMedGoogle Scholar
  39. Sun H, Cocker PJ, Zeeb FD, Winstanley CA (2012) Chronic atomoxetine treatment during adolescence decreases impulsive choice, but not impulsive action, in adult rats and alters markers of synaptic plasticity in the orbitofrontal cortex. Psychopharmacology (Berl) 219:285–301CrossRefGoogle Scholar
  40. Suskauer SJ, Simmonds DJ, Caffo BS, Denckla MB, Pekar JJ, Mostofsky SH (2008) fMRI of intrasubject variability in ADHD: anomalous premotor activity with prefrontal compensation. J Am Acad Child Adolesc Psychiatry 47:1141–1150PubMedCentralPubMedCrossRefGoogle Scholar
  41. Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP (2006) Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 50:755–760PubMedCrossRefGoogle Scholar
  42. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ (2005) A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:647–655PubMedCrossRefGoogle Scholar
  43. Wietecha L, Young J, Ruff D, Dunn D, Findling RL, Saylor K (2012) Atomoxetine once daily for 24 weeks in adults with attention-deficit/hyperactivity disorder (ADHD): impact of treatment on family functioning. Clin Neuropharmacol 35:125–133PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Josep Antoni Ramos-Quiroga
    • 1
    • 2
    • 3
  • Margarida Corominas-Roso
    • 1
    Email author
  • Gloria Palomar
    • 1
  • Nuria Gomez-Barros
    • 1
    • 2
  • Marta Ribases
    • 1
    • 2
    • 4
  • Cristina Sanchez-Mora
    • 1
    • 2
    • 4
  • Rosa Bosch
    • 1
    • 2
  • Mariana Nogueira
    • 1
  • Montserrat Corrales
    • 1
  • Sergi Valero
    • 1
    • 2
  • Miguel Casas
    • 1
    • 2
    • 3
  1. 1.Department of Psychiatry, Hospital Universitari Vall d’Hebron, CIBERSAMUniversitat Autònoma de BarcelonaBarcelonaSpain
  2. 2.Biomedical Network Research Centre on Mental Health (CIBERSAM)MadridSpain
  3. 3.Department of Psychiatry and Legal MedicineUniversitat Autònoma de BarcelonaBarcelonaSpain
  4. 4.Psychiatric Genetics UnitVall d’Hebron Research Institute (VHIR)BarcelonaSpain

Personalised recommendations